Comparative Pharmacology
Head-to-head clinical analysis: CORTAN versus WESTCORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORTAN versus WESTCORT.
CORTAN vs WESTCORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that binds to the glucocorticoid receptor, leading to anti-inflammatory and immunosuppressive effects by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppressing cytokine production.
Topical corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive actions. Binds to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, and suppress cytokine production.
5-60 mg orally once daily, titrated to the lowest effective dose. Maintenance: 5-20 mg daily.
Apply a thin film to affected area twice daily. Use for no longer than 2 consecutive weeks.
None Documented
None Documented
Terminal elimination half-life 1.5–2 hours; clinical context: short duration requires multiple daily doses for sustained effect
Terminal elimination half-life is 2-4 hours. Clinical context: Requires multiple daily applications for sustained effect; systemic accumulation unlikely with topical use.
Renal: 80% as metabolites and unchanged drug; biliary/fecal: 20%
Primarily renal (70-90% as metabolites, <5% unchanged); minor biliary/fecal (10-20%)
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid